Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remdesivir - Gilead Sciences

Drug Profile

Remdesivir - Gilead Sciences

Alternative Names: Captisol-enabled remdesivir; Captisol®-enabled GS 5734; GS-5734; Redyx; VEKLURY; Veklury

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Capital Medical University; China-Japan Friendship Hospital; Chinese Academy of Medical Sciences; Dr Reddys Laboratories; Gilead Sciences; INSERM; National Institute of Allergy and Infectious Diseases; NeuroActiva; Roche
  • Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Phosphorus compounds; Pyridazines; Pyrroles; Small molecules; Triazines
  • Mechanism of Action RNA replicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase III COVID-19 pneumonia
  • Phase II Ebola virus infections
  • Phase I Neurological disorders

Most Recent Events

  • 07 Nov 2022 NeuroRx in collaboration with National Institute of Allergy and Infectious Diseases, University of Copenhagen, Medical Research Council, Kirby Institute, National Heart, Lung, and Blood Institute, Cardiothoracic Surgical Trials Network, and Gilead Sciences completes the phase III TESICO trial for COVID-19 respiratory infection and SARS-COV-2 acute respiratory disease (Monotherapy, Combination therapy) in USA (IV) (NCT04843761)
  • 25 Sep 2022 Pharmacokinetics data from a phase I/II CARAVAN trial in Covid-2019 infections presented at the Annual Meeting of the American College of Clinical Pharmacology (ACCP-2022)
  • 25 Sep 2022 Pharmacokinetics data from a phase I trial in Covid-2019 infections presented at the 2022 American College of Clinical Pharmacology Annual Meeting (ACCP-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top